Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Earlier, Johnson & Johnson Receives FDA Approval For SIMPONI To Treat Moderately To Severely Active Pediatric Ulcerative Colitis

Author: Benzinga Newsdesk | October 08, 2025 03:34am

Approval expands SIMPONI® indication to treat children weighing at least 15 kg with moderately to severely active ulcerative colitis
SIMPONI is the only approved treatment to offer a monthly maintenance dose for this patient population

Posted In: JNJ